// App-Quantinova.ai

AB0801 : EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES

Researchers

Presenter

  • D. Mcgonagle

Principal Investigators

  • I. Mcinnes

  • A. Deodhar

  • G. Schett

  • P. J. Mease

  • M. Shawi

  • S. Kafka

  • C. Karyekar

  • A. Kollmeier

  • E. C. Hsia

  • X. L. Xu

  • S. Sheng

  • P. Agarwal

  • B. Zhou

  • C. T. Ritchlin

  • P. Rahman

Medical Centers

  • Leeds Biomed Res Ctr, U Leeds, Leeds, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • Oregon Health & Science Univ, Portland, United States

  • FAU, Erlangen-Nürnburg, Germany

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • Janssen Scientific Affairs, LLC, Raritan, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

  • University of Rochester Medical Center, Rochester, United States of America

  • Memorial U Newfoundland, St. Johns, Canada

Locations

  • United Kingdom

  • United States

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Tumor necrosis factor

  • Albumin/creatinine

Drug/Treatment

  • Interleukin

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Janssen Research & Development

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved